Versie door Update bot(overleg | bijdragen) op 18 apr 2026 om 18:31 (Nieuwe pagina aangemaakt met '<!-- Hieronder wordt een transclude page aangeroepen --> {{Versions-2.16.840.1.113883.2.4.3.11.60.40.3.9.6(EN)|1|MedicationAgreement-v4.1(2026-1EN)}} <!-- Tot hier de transclude page --> ==General information<!--hdGeneralInformation-->== Name<!--hdName-->: '''nl.zorg.MedicationAgreement''' link=Medicatieafspraak-v4.1(2026-1NL)<BR> Version<!--hdVersion-->: '''4.1''' <br> HCIM Status<!--hdStatus-->:Final<br> Release<!--hdPublication-->:…')
A medication agreement is the agreement between the prescriber and the patient regarding this patient’s use of medication. An agreement to stop or change the medication use is also a medication agreement.
Purpose
The goal of the medication agreement is to provide insight into the agreements reached between the prescriber and the patient on the use of medication.
Information Model
Type
Id
Concept
Card.
Definition
DefinitionCode
Reference
NL-CM:9.6.9580
MedicationAgreement
Root concept of the MedicationAgreement information model. This root concept contains all data elements of the MedicationAgreement information model.
Identification of a medication treatment. A pharmaceutical treatment is defined as a treatment with a medicinal product. The PharmaceuticalTreatmentID is a technical identifier (worldwide and forever unique) that is required to record the relationship between a set of medication-related data elements. An identically defined PharmacotherapeuticTreatmentID has been added to all medication-related Health and Care Information Models (HCIMs): MedicationAgreement, MedicationAdministration2, AdministrationAgreement, MedicationUse2, MedicationDispense, and DispenseRequest.
One or more medication agreements that have been discontinued or modified and for which this agreement is a replacement. When recording a new medication agreement that is intended to discontinue or modify one or more existing agreements, it is possible to explicitly indicate which previous medication agreements the replacement applies to. This reference is used in combination with the corresponding discontinuation type and any reason for changing or discontinuing.
Appointment date + time are required (order of the appointments must be clear in cases with multiple appointments on one day)
NL-CM:9.6.19936
PeriodOfUse::TimeInterval
1
Start date: This is the time at which the agreement was to take effect (or took effect or will take effect). This is the time at which the instructions for use in this agreement start. In the case of an agreement to discontinue use, this is the start date of the original medication agreement. The end date indicates from when the medication is to be discontinued.
Duration: The intended duration of use. E.g. 5 days or 8 weeks. It is not allowed to indicate the duration in months, because different months have a variable duration in days.
End date: The time at which the period of use ends (or ended or will end). In the case of an agreement to discontinue use, this is the time at which the medication is to be discontinued. To avoid confusion between 'to' and 'up until and including', the submission of time is always mandatory for the end date.
With medication for an indefinite period only a start date is indicated.
Permitted units for the duration: hour, day, week, year.
Additional information includes details on the structure of the agreement made that are relevant for pharmacovigilance and fulfillment by the pharmacist. This can be used e.g. to indicate that there was a conscious decision to deviate from the norm or that the agreement is to be structured in a certain way.
See also the Instructions section for more information about use of the element.
Van 8-9-2017 tot 18-9-2017 1x per dag 1 stuk. Vanaf 18-9-2017 staken.
1 stuk
1x per dag
Reumatoïde Artritis
Vanaf 6 maart 2016 1x per week op maandag om 14uur 15 mg (=0,6 ml)
15 mg (=0,6 ml)
1x per week op maandag (14u)
Instructions
The rules about linking an existing PharmaceuticalTreatmentID or to issue a new PharmaceuticalTreatmentID have been determined by the Medication Process information standard established by Nictiz.
Assigning authorities
The identifying numbers are issued by the following authorities
Technical specifications in HL7v3 CDA and HL7 FHIR
To exchange information based on health and care information models, additional, more technical specifications are required.
Not every environment can handle the same technical specifications. For this reason, there are several types of technical specifications:
HL7® version 3 CDA compatible specifications, available through the Nictiz ART-DECOR® environment
HL7® FHIR® compatible specifications, available through the Nictiz environment on the Simplifier FHIR
MedicationAgreement
PharmaceuticalTreatmentID
or as spreadsheet 